Aspirin dangerous for health of heart patients.

[Guest guest]

> Fri, 9 Jul 2004 09:54:09 +0200

 

> " Sepp (Josef) Hasslberger " <sepp

> Aspirin dangerous for health of heart

> patients.

>

> From the site of Mercola -

>

> copied below is an article on aspirin and warfarin

> being ineffective

> and dangerous for people with heart disease - so

> much for the

> " dangerous " interaction of herbs with warfarin. It's

> the drug itself

> that's dangerous and useless.

>

> Let the medicine proponents prove their risk/benefit

> ratio first.

>

> (That brings to mind a recent

>

<http://bmj.bmjjournals.com/cgi/content/full/329/7456/0-g>BMJ

>

> editorial on the subject of medical harm which has

> attracted some

> interesting comments in the subsequent discussion on

> BMJ's website)...

>

> Kind regards

> Sepp

>

>

>

<http://mercola.com/blog/2004/jul/8/aspirin_dangerous_and_ineffective_for_people\

_with_heart_failure>Aspirin

>

> Dangerous and Ineffective for People With Heart

> Failure

>

> Using aspirin for heart disease has been

> controversial for years,

> and now aspirin is in the news again. People with

> heart failure are

> often put on blood-thinning regimens with aspirin or

> sometimes

> Coumadin (warfarin), but a new study indicates that

> this is not

> helpful and could even be harmful. Results from the

> Warfarin/Aspirin

> Study in Heart Failure (WASH) show that aspirin and

> warfarin provide

> no meaningful benefit to patients with heart

> failure. Further, those

> participants who received aspirin were twice as

> likely as patients on

> warfarin to be hospitalized or to die of a

> cardiovascular cause and

> were significantly more likely to have serious

> gastrointestinal

> events.

>

> A better and safer option than aspirin is

> Nattokinase, a powerful

> enzyme--derived from the food natto--that can

> dissolve blood clots

> and has been used safely for over 20 years. Rivaling

> pharmaceutical

> agents, Nattokinase seems to have longer lasting

> beneficial action

> without the potential for abnormal bleeding. Watch

> for more news

> about Nattokinase soon as we will offer this very

> potent all natural

> enzyme on the site this fall.

>

>

>

> The Warfarin/Aspirin Study in Heart failure (WASH):

> a randomized

> trial comparing antithrombotic strategies for

> patients with heart

> failure.

>

> Cleland JG, Findlay I, Jafri S, Sutton G, Falk R,

> Bulpitt C, Prentice

> C, Ford I, Trainer A, Poole-Wilson PA.

>

>

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve & db=pubmed & dopt=Abstra\

ct & list_uids=15215806

>

> Academic Unit, Department of Cardiology, Castlehill

> Hospital,

> University of Hull, Kingston upon Hull, United

> Kingdom.

> J.G.Cleland

>

> BACKGROUND: Heart failure is commonly associated

> with vascular

> disease and a high rate of athero-thrombotic events,

> but the risks

> and benefits of antithrombotic therapy are unknown.

> METHODS: The

> current study was an open-label, randomized,

> controlled trial

> comparing no antithrombotic therapy, aspirin (300

> mg/day), and

> warfarin (target international normalized ratio 2.5)

> in patients with

> heart failure and left ventricular systolic

> dysfunction requiring

> diuretic therapy. The primary objective was to

> demonstrate the

> feasibility and inform the design of a larger

> outcome study. The

> primary clinical outcome was death, nonfatal

> myocardial infarction,

> or nonfatal stroke. RESULTS: Two hundred

> seventy-nine patients were

> randomized and 627 patient-years exposure were

> accumulated over a

> mean follow-up time of 27 +/- 1 months. Twenty-six

> (26%), 29 (32%),

> and 23 (26%) patients randomized to no

> antithrombotic treatment,

> aspirin, and warfarin, respectively, reached the

> primary outcome

> (ns). There were trends to a worse outcome among

> those randomized to

> aspirin for a number of secondary outcomes.

> Significantly (P =.044)

> more patients randomized to aspirin were

> hospitalized for

> cardiovascular reasons, especially worsening heart

> failure.

> CONCLUSIONS: The Warfarin/Aspirin Study in Heart

> failure (WASH)

> provides no evidence that aspirin is effective or

> safe in patients

> with heart failure. The benefits of warfarin for

> patients with heart

> failure in sinus rhythm have not been established.

> Antithrombotic

> therapy in patients with heart failure is not

> evidence based but

> commonly contributes to polypharmacy.

>

>

>

> --

>

> The individual is supreme and finds its way through

> intuition.

> Sepp (Josef) Hasslberger

>

> Personal home page on physics,energy technology,

> social

> and economic issues: http://www.hasslberger.com

>

> Health Supreme: http://www.newmediaexplorer.org/sepp

>

> Antiprohibition and products made from cannabis as a

> raw

> material: http://www.unsaccodicanapa.com

>

> Communication Agents:

> http://www.communicationagents.com/

>

> La Leva di Archimede - freedom of choice

> main site: http://www.laleva.cc

> news: http://www.laleva.org

>

> Robin Good - " Understanding comes from exploration "

> http://www.masternewmedia.org

>

> Trash Your Television!

> http://www.tvturnoff.org/

>

> Not satisfied with news from the tube and other

> controlled media?

> Search the net! There are literally thousands of

> alternative sources

> out there. Start with the following links. (But

> there are many more

> sites with good, timely information.)

>

> http://www.whatreallyhappened.com

> http://www.joevialls.co.uk/

> http://www.padrak.com/alt/911DD.html

>